AP
Acta Pharmaceuticals
United States · Biotech
Develops investigational medicines for early intervention in Alzheimer’s disease.
Product
Acta Pharmaceuticals is a Boston biotechnology company advancing an oral gamma-secretase modulator and potential combination therapies for Alzheimer’s disease. Its research aims to alter amyloid-beta production and intervene earlier in the disease process.
Lead candidate GSM-779690T is being evaluated through a phase 1 program focused on safety, tolerability and pharmacokinetics. The drug is investigational; its clinical efficacy has not been established.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Total seed financing | $24M | Participants not disclosed |